These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30947317)

  • 1. Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
    Li S; Cao Y; Li L; Zhang H; Lu X; Bo C; Kong X; Liu Z; Chen L; Liu P; Jiao Y; Wang J; Ning S; Wang L
    PLoS One; 2019; 14(4):e0214857. PubMed ID: 30947317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.
    Cao Y; Lu X; Wang J; Zhang H; Liu Z; Xu S; Wang T; Ning S; Xiao B; Wang L
    Int J Mol Med; 2017 Feb; 39(2):268-278. PubMed ID: 28075449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a TF-miRNA-gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis.
    Bo C; Zhang H; Cao Y; Lu X; Zhang C; Li S; Kong X; Zhang X; Bai M; Tian K; Saitgareeva A; Lyaysan G; Wang J; Ning S; Wang L
    Sci Rep; 2021 Jan; 11(1):2416. PubMed ID: 33510225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
    Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration in gene expression profile of thymomas with or without myasthenia gravis linked with the nuclear factor-kappaB/autoimmune regulator pathway to myasthenia gravis pathogenesis.
    Guo F; Wang CY; Wang S; Zhang J; Yan YJ; Guan ZY; Meng FJ
    Thorac Cancer; 2019 Mar; 10(3):564-570. PubMed ID: 30734484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.
    Luo Z; Li Y; Liu X; Luo M; Xu L; Luo Y; Xiao B; Yang H
    BMC Med Genomics; 2015 Mar; 8():13. PubMed ID: 25889429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune mechanisms in myasthenia gravis.
    Cavalcante P; Bernasconi P; Mantegazza R
    Curr Opin Neurol; 2012 Oct; 25(5):621-9. PubMed ID: 22941261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of thalidomide on experimental autoimmune myasthenia gravis.
    Crain E; McIntosh KR; Gordon G; Pestronk A; Drachman DB
    J Autoimmun; 1989 Apr; 2(2):197-202. PubMed ID: 2788425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis: from autoantibodies to therapy.
    Mantegazza R; Bernasconi P; Cavalcante P
    Curr Opin Neurol; 2018 Oct; 31(5):517-525. PubMed ID: 30156572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the Comparative Toxicogenomics Database.
    Davis AP; Wiegers TC; King BL; Wiegers J; Grondin CJ; Sciaky D; Johnson RJ; Mattingly CJ
    PLoS One; 2016; 11(5):e0155530. PubMed ID: 27171405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominantly inherited familial myasthenia gravis as a separate genetic entity without involvement of defined candidate gene loci.
    Li F; Szobor A; Croxen R; Anselmo V; Yuan QP; Lindblad K; Schalling M; Komoly S; Beeson D; Larsson C
    Int J Mol Med; 2001 Mar; 7(3):289-94. PubMed ID: 11179509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myasthenia gravis: subgroup classification and therapeutic strategies.
    Gilhus NE; Verschuuren JJ
    Lancet Neurol; 2015 Oct; 14(10):1023-36. PubMed ID: 26376969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis and the neuromuscular junction.
    Querol L; Illa I
    Curr Opin Neurol; 2013 Oct; 26(5):459-65. PubMed ID: 23945282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc L-carnosine protects colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation.
    Odashima M; Otaka M; Jin M; Wada I; Horikawa Y; Matsuhashi T; Ohba R; Hatakeyama N; Oyake J; Watanabe S
    Life Sci; 2006 Nov; 79(24):2245-50. PubMed ID: 16949620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NET-GE: a novel NETwork-based Gene Enrichment for detecting biological processes associated to Mendelian diseases.
    Di Lena P; Martelli PL; Fariselli P; Casadio R
    BMC Genomics; 2015; 16 Suppl 8(Suppl 8):S6. PubMed ID: 26110971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myasthenia gravis treated with immunosuppressive drugs].
    Petrányi G; Szobor A
    Orv Hetil; 1969 Dec; 110(51):2977-80. PubMed ID: 5368684
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept treatment in corticosteroid-dependent myasthenia gravis.
    Rowin J; Meriggioli MN; Tüzün E; Leurgans S; Christadoss P
    Neurology; 2004 Dec; 63(12):2390-2. PubMed ID: 15623708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of HLA-DQA1*0101/2 and DQB1*0502 with myasthenia gravis in southern Iranian patients.
    Yousefipour GA; Salami Z; Farjadian S
    Iran J Immunol; 2009 Jun; 6(2):99-102. PubMed ID: 19561379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial autoimmune myasthenia gravis.
    Tan JH; Ho KH
    Singapore Med J; 2001 Apr; 42(4):178-9. PubMed ID: 11465320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.